

Parul Doshi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4980890/publications.pdf>

Version: 2024-02-01

17
papers

1,225
citations

623188

14
h-index

887659

17
g-index

18
all docs

18
docs citations

18
times ranked

2164
citing authors

#	ARTICLE	IF	CITATIONS
1	Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens. <i>Haematologica</i> , 2020, 105, 1032-1041.	1.7	29
2	STK11 and KEAP1 mutations as prognostic biomarkers in an observational real-world lung adenocarcinoma cohort. <i>ESMO Open</i> , 2020, 5, e000706.	2.0	139
3	Blood Transfusion Management and Transfusion-Related Outcomes in Daratumumab-Treated Patients With Relapsed or Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 44-51.	0.2	30
4	Daratumumab binds to mobilized CD34+ cells of myeloma patients in vitro without cytotoxicity or impaired progenitor cell growth. <i>Experimental Hematology and Oncology</i> , 2018, 7, 27.	2.0	15
5	Mammary tumor-derived CCL2 enhances pro-metastatic systemic inflammation through upregulation of IL1 β in tumor-associated macrophages. <i>Oncolmunology</i> , 2017, 6, e1334744.	2.1	81
6	The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia-Microenvironment Interactions in Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2017, 23, 1493-1505.	3.2	38
7	International validation of a dithiothreitol (DTT)-based method to resolve the daratumumab interference with blood compatibility testing. <i>Transfusion</i> , 2016, 56, 2964-2972.	0.8	76
8	Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance. <i>Haematologica</i> , 2016, 101, e339-e342.	1.7	34
9	Resolving the daratumumab interference with blood compatibility testing. <i>Transfusion</i> , 2015, 55, 1545-1554.	0.8	204
10	When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy. <i>Transfusion</i> , 2015, 55, 1555-1562.	0.8	131
11	International Validation of a Dithiothreitol (DTT)-Based Method to Resolve the Daratumumab Interference with Blood Compatibility Testing. <i>Blood</i> , 2015, 126, 3567-3567.	0.6	2
12	Antitumor Efficacy of the Anti-Interleukin-6 (IL-6) Antibody Siltuximab in Mouse Xenograft Models of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2014, 9, 974-982.	0.5	79
13	Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers. <i>Molecular Oncology</i> , 2014, 8, 1231-1239.	2.1	85
14	Direct in Vitro Comparison of Daratumumab with Surrogate Analogs of CD38 Antibodies MOR03087, SAR650984 and Ab79. <i>Blood</i> , 2014, 124, 3474-3474.	0.6	150
15	CNTO 95, a fully human anti α v integrin antibody, inhibits cell signaling, migration, invasion, and spontaneous metastasis of human breast cancer cells. <i>Clinical and Experimental Metastasis</i> , 2008, 25, 139-148.	1.7	83
16	Enhanced ability of the progenipoietin-1 to suppress apoptosis in human hematopoietic cells. <i>International Journal of Molecular Medicine</i> , 2002, 10, 385.	1.8	2
17	Two α -tubulin genes of <i>Aspergillus nidulans</i> encode divergent proteins. <i>Molecular Genetics and Genomics</i> , 1991, 225, 129-141.	2.4	43